
An NIH-led team describes how a non-NMDA-blocking ketamine metabolite moved from back-translational discovery to 4 ongoing phase 2 trials.

Dr Johnston is a postdoctoral fellow at National Institute of Mental Health.

An NIH-led team describes how a non-NMDA-blocking ketamine metabolite moved from back-translational discovery to 4 ongoing phase 2 trials.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.

Entactogen research targets social anxiety and isolation across diagnoses, pairing “plasticity windows” with psychotherapy amid shifting FDA scrutiny and evolving trial designs.

Experts weigh MDMA-like entactogens for social anxiety and depression, neuroplasticity windows, and what FDA setbacks mean for next-wave treatments.

In this inaugural episode, experts discuss the limitations of current diagnosis-based frameworks in suicide research, emphasizing the need for more targeted interventions.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.